Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

therapeutic

Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Section 203: Advanced Epigenetic and Chromatin Therapy in CBS/PSP</th> </tr> <tr> <td class=“label”>Target</td> <td>Change in CBS/PSP</td> </tr> <tr> <td class=“label”>H3K9ac</td> <td>Decreased</td> </tr> <tr> <td class=“label”>H3K27ac</td> <td>Decreased</td> </tr> <tr> <td class=“label”>H4K12ac</td> <td>Decreased</td> </tr> <tr> <td class=“label”>Global DNA methylation</td> <td>Increased</td> </tr> <tr> <td class=“label”>SIRT1 activity</td> <td>Decreased</td> </tr> <tr> <td class=“label”>BET proteins</td> <td>Increased</td> </tr> <tr> <td class=“label”>Drug</td> <td>Trial Phase</td> </tr> <tr> <td class=“label”>Valproic Acid</td> <td>Phase 2 (PSP)</td> </tr> <tr> <td class=“label”>Vorinostat</td> <td>Phase 1/2</td> </tr> <tr> <td class=“label”>Panobinostat</td> <td>Phase 1</td> </tr> <tr> <td class=“label”>HDAC6 inhibitors</td> <td>Preclinical</td> </tr> <tr> <td class=“label”>Target</td> <td>Drug</td> </tr> <tr> <td class=“label”>BRD4</td> <td>JQ1/OTX015</td> </tr> <tr> <td class=“label”>CHD4</td> <td>Inhibitors</td> </tr> <tr> <td class=“label”>MBT domain proteins</td> <td>Small molecules</td> </tr> <tr> <td class=“label”>Epigenetic Agent</td> <td>Levodopa Interaction</td> </tr> <tr> <td class=“label”>Valproic Acid</td> <td>↑ levels (CYP inhibition), monitor</td> </tr> <tr> <td class=“label”>Entinostat</td> <td>Potential interaction, monitor</td> </tr> <tr> <td class=“label”>Resveratrol</td> <td>Minimal interaction</td> </tr> <tr> <td class=“label”>JQ1 (research)</td> <td>Unknown</td> </tr> <tr> <td class=“label”>Rank</td> <td>Therapy</td> </tr> <tr> <td class=“label”>1</td> <td>Valproic Acid</td> </tr> <tr> <td class=“label”>2</td> <td>HDAC6 Inhibitors</td> </tr> <tr> <td class=“label”>3</td> <td>Resveratrol</td> </tr> <tr> <td class=“label”>4</td> <td>BET Inhibitors</td> </tr> </table>

Epigenetic dysregulation is a hallmark of tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Pathological tau accumulation is associated with widespread changes in the epigenetic landscape, including histone hypoacetylation, DNA hypermethylation, and altered chromatin accessibility. These changes contribute to transcriptional dysregulation of genes involved in neuronal survival, synaptic function, and proteostasis[@grayson2020].

This section covers pharmacological approaches to modulate the epigenetic machinery in CBS/PSP:

  • Histone deacetylase (HDAC) inhibitors: Restore histone acetylation balance
  • DNA methyltransferase (DNMT) inhibitors: Reverse abnormal DNA methylation patterns
  • Chromatin remodeling: BET inhibitors and chromatin reader modulators
  • Sirtuin modulators: Target Class III HDACs (SIRT1, SIRT2)
  • Drug interactions: Manage combination with levodopa and rasagiline

1. Epigenetic Dysregulation in CBS/PSP

1.1 Pathological Epigenome Changes

flowchart TD
    A["Tau Pathology"] --> B["Epigenetic Dysregulation"]
    B --> C["Histone Modifications"]
    B --> D["DNA Methylation"]
    B --> E["Chromatin Accessibility"]

    C --> C1["HDAC upregulation"]
    C --> C2["Hypoacetylation"]
    C --> C3["Transcription suppression"]

    D --> D1["DNMT activity"]
    D --> D2["Hypermethylation"]
    D --> D3["Gene silencing"]

    E --> E1["Closed chromatin"]
    E --> E2["Reduced transcription"]
    E --> E3["Neuronal dysfunction"]

    style C1 fill:#3b1114,stroke:#333
    style D1 fill:#3b1114,stroke:#333
    style E1 fill:#3b1114,stroke:#333

1.2 Key Epigenetic Targets

2. Histone Deacetylase (HDAC) Inhibitors

2.1 Mechanism of Action

HDACs remove acetyl groups from histone lysine residues, leading to chromatin condensation and transcriptional repression. In CBS/PSP, HDAC activity is elevated, contributing to suppressed expression of neuroprotective genes. HDAC inhibitors restore acetyltransferase balance, reopening chromatin for transcription of survival genes[@rouaux2017].

flowchart LR
    A["Normal Neuron"] --> B["Balanced HAT/HDAC"]
    A --> C["Open chromatin"]
    A --> D["Normal transcription"]

    E["Tauopathy Neuron"] --> F["Elevated HDAC"]
    E --> G["Hypoacetylation"]
    E --> H["Closed chromatin"]
    E --> I["Suppressed transcription"]

    J["HDAC Inhibitor"] --> K["HDAC blockade"]
    J --> L["Restored acetylation"]
    J --> M["Reopened chromatin"]
    J --> N["Neuronal protection"]

    F -.-> J
    H -.-> J

2.2 HDAC Inhibitor Classes

Class I HDAC Inhibitors (HDAC1, 2, 3, 8)

Valproic Acid (VPA)

  • Mechanism: Pan-class I HDAC inhibitor
  • Evidence: Reduces tau phosphorylation in vivo via GSK-3β inhibition[@min2019]
  • Dosing: 500-1000 mg/day (mood stabilizer dose)
  • CBS/PSP relevance: VPA shows promise but mixed results in clinical studies
  • Drug interactions: May affect levodopa metabolism via CYP enzyme inhibition; monitor for increased sedation when combined with rasagiline

Entinostat (MS-275)

  • Mechanism: Class I-selective HDAC inhibitor
  • Evidence: Shows neuroprotection in tauopathy models
  • Status: Preclinical/Phase 1

Class II HDAC Inhibitors (HDAC4, 5, 6, 9, 10)

HDAC6-Selective Inhibitors

  • Target: HDAC6 (cytoplasmic, deacetylates tubulin)
  • Examples: Tubastatin A, ACY-1215 (ricolinostat)
  • Mechanism: Increase tubulin acetylation, improve axonal transport
  • Advantage: Lower toxicity than pan-HDAC inhibitors
  • CBS/PSP relevance: Particularly relevant for axonal transport deficits

Class III HDAC (Sirtuin) Modulators

SIRT1 Activators

  • Resveratrol: 250-500 mg/day, shows cognitive benefit in some trials
  • SRT2104: More potent SIRT1 activator, in development
  • Mechanism: Deacetylates PGC-1α, FOXO, p53 — promotes mitochondrial biogenesis and stress resistance[@settel2023]

SIRT2 Inhibitors

  • AGK2: SIRT2-selective inhibitor
  • Mechanism: SIRT2 inhibition reduces tau acetylation and aggregation
  • Evidence: Neuroprotective in PSP models

2.3 Clinical Evidence

3. DNA Methyltransferase (DNMT) Inhibitors

3.1 DNA Methylation Abnormalities in CBS/PSP

DNA methylation patterns are altered in tauopathies, with global hypermethylation observed in brain tissue. This leads to silencing of genes involved in neuronal function, synaptic plasticity, and stress response. DNMT inhibitors can reverse these patterns[@chen2019].

flowchart TD
    A["Tau pathology"] --> B["DNMT overexpression"]
    B --> C["Global DNA hypermethylation"]
    C --> D["Gene promoter silencing"]
    D --> E["Reduced neurotrophic factors"]
    D --> F["Impaired synaptic genes"]
    D --> G["Stress response suppression"]

    H["DNMT Inhibitor"] --> I["Demethylation"]
    I --> J["Gene reactivation"]
    J --> K["Neuroprotection"]

3.2 DNMT Inhibitor Approaches

5-Azacytidine (Vidaza)

  • Mechanism: Nucleoside analog incorporation into DNA → irreversible DNMT binding
  • Evidence: Reverses methylation in Alzheimer’s models, promotes neuronal differentiation
  • Challenges: Hematological toxicity, limited CNS penetration
  • CBS/PSP relevance: Being explored for neurodegenerative applications

RG108

  • Mechanism: Non-nucleoside DNMT inhibitor
  • Advantage: Lower toxicity than nucleoside analogs
  • Status: Preclinical

Procaine

  • Mechanism: Local anesthetic with DNMT inhibitory properties
  • Evidence: Shows memory enhancement in AD models
  • Dosing: 100-200 mg/day (off-label)
  • Drug interactions: May interact with levodopa via shared transporters

3.3 Clinical Considerations

DNMT inhibitor therapy for neurodegenerative disease remains largely preclinical. Key challenges include:

  • Blood-brain barrier penetration
  • Off-target effects from global demethylation
  • Optimal dosing for CNS applications
  • Combination with existing therapies

4. Chromatin Remodeling Approaches

4.1 BET Bromodomain Inhibitors

BET proteins (BRD2, BRD3, BRD4, BRDT) are chromatin “readers” that bind acetylated histones and regulate transcription. In tauopathies, BET activity is elevated, driving expression of inflammatory genes and contributing to pathology. BET inhibitors block this interaction, reducing harmful transcription[@kelley2019].

JQ1

  • Mechanism: First-generation BET inhibitor
  • Evidence: Reduces tau toxicity in models, decreases neuroinflammation
  • Challenge: Short half-life, limited BBB penetration

OTX015 (Birabresib)

  • Mechanism: BET inhibitor with improved pharmacokinetics
  • Status: Phase 1 in oncology, being adapted for neurodegeneration
  • CNS penetration: Being optimized for brain delivery

IBET151

  • Mechanism: Second-generation BET inhibitor
  • Evidence: Shows efficacy in PSP models
  • Advantage: Better tolerability than JQ1

4.2 Chromatin Reader Modulators

4.3 Combination Approaches

Epigenetic therapies may be combined for synergistic effect:

  • HDAC + DNMT inhibitors: Sequential treatment to fully reset epigenetic landscape
  • HDAC + BET inhibitors: Target multiple levels of transcriptional dysregulation
  • SIRT1 activator + HDAC inhibitor: Complementary mechanisms (Class III + Class I/II)

5. Clinical Implementation

5.1 Patient Selection

Ideal candidates for epigenetic therapy:

  • Early-stage CBS/PSP (preserved neuronal function)
  • Confirmed tauopathy (tau PET positive)
  • Intact blood-brain barrier
  • No significant comorbidities

Considerations:

  • Genetic testing for epigenetic enzyme variants may inform response
  • Biomarker monitoring (neurofilament light chain) to track progression

5.2 Drug Interactions with Current Medications

Levodopa interactions:

  • HDAC inhibitors may affect levodopa metabolism through CYP enzyme modulation
  • Monitor for increased dyskinesias or reduced efficacy
  • Timing: Separate dosing by 2+ hours

Rasagiline interactions:

  • MAO-B inhibitors may have synergistic neuroprotective effects with HDAC inhibitors
  • Generally compatible, monitor for serotonin syndrome if adding serotonergic agents
  • Additive effects on mitochondrial function

5.3 NET Assessment Considerations

Norepinephrine transporter (NET) imaging can help evaluate:

  • Autonomic dysfunction extent
  • Noradrenergic pathway integrity
  • Potential for noradrenergic-based therapies

Combining NET assessment with epigenetic therapy monitoring may help predict response.

6. Therapeutic Recommendations

6.1 Priority Approaches

6.2 Monitoring Parameters

  • Biomarkers: NfL, p-tau181, GFAP every 3-6 months
  • Clinical: Motor Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), PSP Rating Scale
  • Imaging: MRI volumetrics, FDG-PET for metabolic response
  • Epigenetic markers: Where available, chromatin accessibility assays

7. Future Directions

  • Epigenetic editing: CRISPR-dCas9-based approaches for precise epigenetic modification (see Epigenetic Editing and CRISPR Approaches)
  • Combination trials: HDAC inhibitors + anti-tau antibodies
  • Personalized epigenomics: Patient-specific epigenetic profiling to guide therapy selection
  • Novel delivery: Nanoparticle-based CNS-targeted delivery of epigenetic agents

8. Key References

  1. Grayson et al., Epigenetic alterations in tauopathies (2020)
  2. Rouaux & Arendt, Class I HDAC manipulation for neurodegenerative diseases (2017)
  3. Bardai et al., HDAC dysfunction in tauopathies (2018)
  4. Chen et al., DNA hypomethylation in AD and tauopathies (2019)
  5. Kelley et al., BET inhibition for tauopathies (2019)
  6. Min et al., HDAC inhibitor valproic acid reduces tau phosphorylation (2019)
  7. Settel et al., Sirtuin 1 activation in tauopathy models (2023)
  8. Park et al., Pan-HDAC inhibitor vorinostat in PSP (2022)

Related Pages

References

  1. Grayson DR, et al., Epigenetic alterations in the brains of patients with tauopathies (2020)
  2. Rouaux C, et al., Class I HDAC manipulation for treatment of neurodegenerative diseases (2017)
  3. Bardai FH, et al., Histone deacetylase dysfunction in tauopathies (2018)
  4. Chen X, et al., DNA hypomethylation in Alzheimer’s disease and tauopathies (2019)
  5. Fischer A, et al., HDAC inhibitor therapy for cognitive enhancement (2010)
  6. Kelley MW, et al., BET bromodomain inhibition as a therapeutic strategy for tauopathies (2019)
  7. Min SW, et al., HDAC inhibitor valproic acid reduces tau phosphorylation in vivo (2019)
  8. Ricotta R, et al., Epigenetic therapy for neurodegenerative disease: clinical landscape (2020)
  9. Settel N, et al., Sirtuin 1 activation in tauopathy models: neuroprotection mechanisms (2023)
  10. Park J, et al., Pan-HDAC inhibitor vorinostat in PSP: mechanism and rationale (2022)